Evidence map›Paper›PMID 33087104›Full record

ArticleJournal of nanobiotechnology2020

Designed proteinoid polymers and nanoparticles encapsulating risperidone for enhanced antipsychotic activity.

L Lugasi, I Grinberg, S Rudnick-Glick, E Okun, H Einat, S Margel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

L LugasiDepartment of Chemistry, The Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, 5290002, Ramat Gan, Israel.
I GrinbergDepartment of Chemistry, The Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, 5290002, Ramat Gan, Israel.
S Rudnick-GlickDepartment of Chemistry, The Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, 5290002, Ramat Gan, Israel.
E OkunThe Mina and Everard Goodman, Faculty of Life Sciences, Bar-Ilan University, 5290002, Ramat Gan, Israel.
H EinatThe School of Behavioral Sciences, Tel Aviv-Yaffo Academic College, 6818211, Tel Aviv, Israel.
S MargelDepartment of Chemistry, The Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, 5290002, Ramat Gan, Israel. Shlomo.margel@biu.ac.il.ORCID http://orcid.org/0000-0001-6524-8179

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNanoparticles (NPs) incorporating drug formulations can be used to facilitate passage through biological barriers including the blood-brain barrier (BBB) and increase drug delivery and bioavailability. Hence, NP-based administration may enhance the efficiency of current antipsychotics. Encapsulation within NPs can resolve aqueous solubility problems that not only reduce permeability through the BBB but also affect targeting. The present study describes a new drug delivery system based on proteinoid NPs to explore the possibility of improving drug efficacy. Risperidone (RSP) is a commonly used atypical antipsychotic medication, and was therefore selected for encapsulation by proteinoid NPs.

resultsProteinoid polymers with high molecular weight and low polydispersity were synthesized from L-amino acids and poly-L-lactic acid (PLLA) by thermal step-growth polymerization mechanism. RSP-loaded proteinoid NPs were then prepared using a self-assembly process in the presence of RSP, followed by PEGylation. The optimal PEGylated RSP-loaded NPs were characterized in terms of diameter and size distribution, drug loading, ζ-potential, cytotoxicity, biodistribution, and psychopharmacological effects. The findings indicate significantly higher antipsychotic activity of drug-loaded proteinoid NPs compared to free RSP.

conclusionsProteinoid NPs enhance RSP delivery and may potentially increase drug efficiency by reducing dosage and side effects.

Indexed as

Amino AcidsAnimalsAntipsychotic AgentsBiological TransportBlood-Brain BarrierCell SurvivalDrug CompoundingDrug LiberationHumansMaleMice, Inbred BALB CNanocapsulesPolyestersPolyethylene GlycolsPolymerizationPorosityAmino AcidsAntipsychotic AgentsNanocapsulesPolyestersPolyethylene Glycolspoly(lactide)RisperidoneAntipsychotic therapyDrug deliveryProteinoid nanoparticlesRisperidoneSelf-assembly

Identifiers

PMID33087104
PMCPMC7580026

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.